The ECE1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the ECE1 gene in the human HT29 colorectal adenocarcinoma cell line. ECE1 encodes endothelin-converting enzyme-1, a type II integral membrane zinc metalloprotease that plays a pivotal role in bioactive peptide processing. The polyclonal knockout pool, generated by CRISPR/Cas9-mediated gene editing, provides a heterogeneous loss-of-function model suitable for population-level analyses, bypassing clonal artifacts and enabling robust functional studies.
The parental HT29 cell line is a widely used human epithelial model derived from a primary colorectal adenocarcinoma of a 44-year-old female. HT29 cells retain key characteristics of intestinal epithelium and are extensively applied in colorectal cancer research to examine tumor growth, differentiation, and metastatic behavior. Their genetic and phenotypic stability makes them a dependable platform for investigating signaling mechanisms underlying colorectal oncogenesis.
At the molecular level, ECE1 catalyzes the proteolytic cleavage of inactive big endothelin-1 into active endothelin-1 (EDN1), a potent vasoconstrictor and mitogen. EDN1 then binds to G-protein-coupled endothelin receptors type A (EDNRA) and type B (EDNRB), initiating downstream cascades that include the MAPK/ERK pathway (MAPK3/MAPK1), the PI3K/AKT pathway (AKT1), and the RhoA/ROCK pathway (RHOA/ROCK1). ECE1 also processes additional vasoactive peptides such as bradykinin, neurotensin, and substance P, linking it to broader signaling networks. Its expression is upregulated by proinflammatory cytokines TNF-?? and IL-1??, growth factor TGF-??, and transcription factors NF-??B and AP-1, reflecting integration with inflammatory and proliferative cues.
In colorectal cancer, aberrant endothelin signaling promotes malignant phenotypes including uncontrolled proliferation, enhanced migration and invasion, and angiogenesis-driven metastasis. Disruption of ECE1 in HT29 cells abrogates the endogenous production of active endothelin-1, thereby attenuating these tumorigenic processes. This knockout model allows researchers to dissect the contribution of ECE1 to colorectal cancer progression and to explore crosstalk with other critical pathways such as Wnt and EGFR, which are frequently co-opted in colorectal tumors. It also serves as a platform for testing the therapeutic efficacy of endothelin receptor antagonists (e.g., bosentan) in a colorectal cancer context.
These polyclonal ECE1 knockout cells are suited for a broad array of functional assays, including Western blotting and ELISA for EDN1 detection, RT-qPCR for gene expression profiling of downstream targets, and cell-based assays for proliferation (MTT), migration, and invasion (transwell). Angiogenic potential can be assessed via tube formation assays, while signaling dynamics may be monitored by phospho-flow cytometry for MAPK and AKT activation. The cells are amenable to transcriptomic studies (RNA-seq) and pharmacological screens with agents targeting the endothelin pathway. For further information or technical assistance, please contact Ascent Research.
